And here's the $NKTR press release: https://t.co/RU1L5btmCJ
My story: Eczema drug from Nektar Therapeutics $NKTR maintains skin responses in one-year study https://t.co/WT9ubPD3Fe
$NKTR here we go! Rezpeg maintenance data in atopic dermatitis. The big picture: 71% of patients on monthly rezpeg maintained their induction EASI75 response at one year. 83% of patients on quarterly rezpeg achieved the same. My (non-expert) view: The results from Nektar’s maintenance study met and in some cases exceeded investor expectations — positioning rezpeg as a treatment with the potential to compete strongly against Dupixent and Ebglyst. I’m eager to hear how @A_May_MD (actual expert) sees the rezpeg maintenance study results. I assume he’ll opine shortly. I spoke to the Nektar folks last night. They are pleased, as you’d expect: “When you compare our results competitively, we’re showing better efficacy with less frequent injections,” Mary Tagliaferri, Nektar’s chief medical officer, told me. Jonathan Zalevsky, Nektar’s head of R&D, added, “I think we've shown some very differentiating features and some really deepening responses in patients that are treated with rezpeg. You want to drive as many patients to clearance of disease. And that's what reveals itself in this dataset.” Nektar is sharing a lot more data during its conference call at 8 am ET. You can read my full story in the link below. Please do!
Nektar Therapeutics $NKTR is trying to stage a comeback. But a big test awaits https://t.co/5bKmgSnx9R
In this week's Biotech Scorecard newsletter: -- A preview of the $NKTR rezpeg maintenance data in atopic dermatitis. I also chatted with CEO Howard Robin during JPM Week. -- A deeper look at $CORT and relacorilant's liver tox problem. Why the drug's future in Cushing's and ovarian cancer are in jeopardy. Links below...
$NKTR slide presentation https://t.co/K4wBzlH8Sg
$NKTR messy rezpeg data in AA? https://t.co/kjrYN0999F
$NKTR fans… next time! https://t.co/WINRfuVzcQ
